Detalhe da pesquisa
1.
Single-cell protein activity analysis identifies recurrence-associated renal tumor macrophages.
Cell
; 184(11): 2988-3005.e16, 2021 05 27.
Artigo
Inglês
| MEDLINE | ID: mdl-34019793
2.
Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial.
Oncologist
; 29(3): 254-262, 2024 Mar 04.
Artigo
Inglês
| MEDLINE | ID: mdl-38262444
3.
A phase 1b open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of py314 in combination with pembrolizumab in patients with advanced renal cell carcinoma.
Invest New Drugs
; 42(2): 179-184, 2024 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-38372949
4.
PADRES: a phase 2 clinical trial of neoadjuvant axitinib for complex partial nephrectomy.
BJU Int
; 133(4): 425-431, 2024 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-37916303
5.
Treatment of renal cell carcinoma: Current status and future directions.
CA Cancer J Clin
; 67(6): 507-524, 2017 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-28961310
6.
Plain language summary looking at how long side effects last after treatment with axitinib is stopped in people with advanced renal cell carcinoma.
Future Oncol
; 19(40): 2623-2629, 2023 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-37526095
7.
LITESPARK-012: pembrolizumab plus lenvatinib with or without belzutifan or quavonlimab for advanced renal cell carcinoma.
Future Oncol
; 19(40): 2631-2640, 2023 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-37882432
8.
Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma.
Cancer
; 128(11): 2085-2097, 2022 06 01.
Artigo
Inglês
| MEDLINE | ID: mdl-35383908
9.
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
N Engl J Med
; 380(12): 1116-1127, 2019 03 21.
Artigo
Inglês
| MEDLINE | ID: mdl-30779529
10.
Approaches to First-Line Therapy for Metastatic Clear Cell Renal Cell Carcinoma.
Curr Oncol Rep
; 24(6): 695-702, 2022 06.
Artigo
Inglês
| MEDLINE | ID: mdl-35247142
11.
Pembrolizumab plus axitinib versus sunitinib in metastatic renal cell carcinoma: outcomes of Japanese patients enrolled in the randomized, phase III, open-label KEYNOTE-426 study.
Int J Clin Oncol
; 27(1): 154-164, 2022 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-34800178
12.
Hydroxychloroquine as Pre-exposure Prophylaxis for Coronavirus Disease 2019 (COVID-19) in Healthcare Workers: A Randomized Trial.
Clin Infect Dis
; 72(11): e835-e843, 2021 06 01.
Artigo
Inglês
| MEDLINE | ID: mdl-33068425
13.
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.
N Engl J Med
; 378(14): 1277-1290, 2018 Apr 05.
Artigo
Inglês
| MEDLINE | ID: mdl-29562145
14.
Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study.
Lancet Oncol
; 21(1): 95-104, 2020 01.
Artigo
Inglês
| MEDLINE | ID: mdl-31810797
15.
Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial.
Lancet Oncol
; 21(12): 1563-1573, 2020 12.
Artigo
Inglês
| MEDLINE | ID: mdl-33284113
16.
Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events.
Br J Cancer
; 123(6): 898-904, 2020 09.
Artigo
Inglês
| MEDLINE | ID: mdl-32587360
17.
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial.
Lancet
; 393(10189): 2404-2415, 2019 06 15.
Artigo
Inglês
| MEDLINE | ID: mdl-31079938
18.
Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma.
BJU Int
; 126(1): 73-82, 2020 07.
Artigo
Inglês
| MEDLINE | ID: mdl-32233107
19.
Angiogenic and immunomodulatory biomarkers in axitinib-treated patients with advanced renal cell carcinoma.
Future Oncol
; 16(17): 1199-1210, 2020 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-32363929
20.
Systemic therapy for advanced clear cell renal cell carcinoma after discontinuation of immune-oncology and VEGF targeted therapy combinations.
BMC Urol
; 20(1): 84, 2020 Jul 02.
Artigo
Inglês
| MEDLINE | ID: mdl-32616076